Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,237 | 428 | 3,781 |
| Samples | 866 | 135 | 723 |
| Peptides | 641 | 91 | 573 |
Function
GRIA2 · Glutamate ionotropic receptor AMPA type subunit 2
Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain and are activated in a variety of normal neurophysiologic processes. This gene product belongs to a family of glutamate receptors that are sensitive to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and function as ligand-activated cation channels. These channels are assembled from 4 related subunits, GRIA1-4. The subunit encoded by this gene (GRIA2) is subject to RNA editing (CAG->CGG; Q->R) within the second transmembrane domain, which is thought to render the channel impermeable to Ca(2+). Human and animal studies suggest that pre-mRNA editing is essential for brain function, and defective GRIA2 RNA editing at the Q/R site may be relevant to amyotrophic lateral sclerosis (ALS) etiology. Alternative splicing, resulting in transcript variants encoding different isoforms, (including the flip and flop isoforms that vary in their signal transduction properties), has been noted for this gene. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
7 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000264426 | P42262 | 935 | 598 |
| ENST00000296526 | P42262-2 | 845 | 574 |
| ENST00000507898 | P42262-4 | 821 | 557 |
| ENST00000393815 | P42262-4 | 820 | 556 |
| ENST00000645636 | P42262-3 | 814 | 564 |
| ENST00000703717 | A0A994J4F1* | 1 | 1 |
| ENST00000703751 | A0A994J6Y8* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 598 amino-acid changes on canonical ENST00000264426 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GRIA2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GRIA2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Melanoma | 13/210 6% | 137/1899 7% |
| Endometrial Carcinoma | 6/42 14% | 30/612 5% |
| Other Solid Cancers | 0/94 0% | 63/1515 4% |
| Non-Small Cell Lung Carcinoma | 22/304 7% | 44/1390 3% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Colorectal Carcinoma | 26/143 18% | 90/3239 3% |
| Gastric Carcinoma | 4/74 5% | 57/1809 3% |
| Plasma Cell Myeloma | 1/44 2% | 8/305 3% |
| Unknown | 0/10 0% | 1/29 3% |
| Neuroendocrine Tumour | 14/154 9% | 4/577 1% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 18/810 2% |
| Cervical Carcinoma | 1/35 3% | 10/422 2% |
| Esophageal Carcinoma | 2/23 9% | 17/769 2% |
| Small Cell Lung Carcinoma | 3/9 33% | 14/752 2% |
| Head and Neck Carcinoma | 4/85 5% | 29/1574 2% |
| Ovarian Carcinoma | 3/109 3% | 18/998 2% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 32/2550 1% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Hepatocellular Carcinoma | 0/46 0% | 27/2210 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 7/88 8% | 19/2534 1% |
| Osteosarcoma | 1/45 2% | 1/166 1% |
| Biliary Tract Carcinoma | 1/54 2% | 8/950 1% |
| Prostate Carcinoma | 2/13 15% | 17/2105 1% |
| Mesothelioma | 1/62 2% | 1/165 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Other Sarcomas | 2/69 3% | 3/699 0% |
| Non-Cancerous | 0/104 0% | 6/830 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
Mutation Distribution
Where GRIA2 is mutated · all tissues, split by cell line vs tissue
How many mutations in GRIA2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,237 mutations in GRIA2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|